Predictors of relapse and engagement in care one year after ending services in an urban safety net coordinated specialty care program for first episode psychosis

被引:2
作者
Hyatt, Andrew [1 ,2 ,3 ]
Mullin, Brian [1 ]
Hasler, Victoria [1 ,2 ]
Madore, Drew [1 ,2 ]
Progovac, Ana M. [1 ,2 ]
Le Cook, Benjamin [1 ,2 ]
DeLisi, Lynn E. [1 ,2 ]
机构
[1] Dept Psychiat, Cambridge Hlth Alliance, 1493 Cambridge St, Cambridge, MA 02139 USA
[2] Harvard Med Sch, Dept Psychiat, 25 Shattuck St, Boston, MA 02115 USA
[3] 26 Cent St, Somerville, MA 02143 USA
关键词
Schizophrenia; Psychosis; Coordinated specialty care; cannabis; Health services; RANDOMIZED CONTROLLED-TRIAL; EARLY INTERVENTION; CANNABIS USE; 1ST-EPISODE PSYCHOSIS; DISPARITIES; SCHIZOPHRENIA; MULTICENTER; MORTALITY; OUTCOMES; ADULTS;
D O I
10.1016/j.schres.2023.12.022
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: This study aimed to identify risk factors for relapse (psychiatric emergency department visits or hospitalization) and lack of follow-up with outpatient psychiatric care in the 12 months after ending services in an urban safety net coordinated specialty care (CSC) program for first episode psychosis (FEP). Methods: The study population (n = 143) were individuals with FEP who had any CSC care between 2014 and 2021. To identify risk factors for relapse and follow up after exit, multivariable logistic regression was performed using data from electronic health records and linked insurance claims data. Results: Individuals with any emergency department visit or hospitalization 12 months prior to ending CSC (aOR = 4.69, 95 % CI 1.78-12.34) and those who were using cannabis at last CSC contact (aOR = 4.06, 95 % CI 1.56-10.56) had a higher risk of relapse after ending CSC services. Cannabis use at last contact was also associated with lower rates of outpatient psychiatric follow-up (aOR = 0.32, 95 % CI 0.12-0.94), while CSC duration in months had a small positive association with post-CSC psychiatric follow-up. There were no differences in relapse or follow-up by race or ethnicity, primary diagnosis, or medication usage. Conclusions: Prior relapse during CSC predicted relapse in the 12 months after ending CSC services, but not outpatient follow up. Cannabis use predicted both a higher rate of relapse and a lower rate of follow up after ending services. There were no differences by race or ethnicity in our sample, suggesting that once individuals engaged in FEP care there were no evident disparities in the observed outcomes.
引用
收藏
页码:140 / 146
页数:7
相关论文
共 45 条
  • [41] Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis
    Schoeler, Tabea
    Monk, Anna
    Sami, Musa B.
    Klamerus, Ewa
    Foglia, Enrico
    Brown, Ruth
    Camuri, Giulia
    Altamura, A. Carlo
    Murray, Robin
    Bhattacharyya, Sagnik
    [J]. LANCET PSYCHIATRY, 2016, 3 (03): : 215 - 225
  • [42] Ten-Year Follow-up of the OPUS Specialized Early Intervention Trial for Patients With a First Episode of Psychosis
    Secher, Rikke Gry
    Hjorthoj, Carsten Rygaard
    Austin, Stephen F.
    Thorup, Anne
    Jeppesen, Pia
    Mors, Ole
    Nordentoft, Merete
    [J]. SCHIZOPHRENIA BULLETIN, 2015, 41 (03) : 617 - 626
  • [43] Mind the Gap: Developing an Integrated Behavioral Health Home to Address Health Disparities in Serious Mental Illness
    Tepper, Miriam C.
    Cohen, Alexander M.
    Progovac, Ana M.
    Ault-Brutus, Andrea
    Leff, H. Stephen
    Mullin, Brian
    Cunningham, Carrie M.
    Le Cook, Benjamin
    [J]. PSYCHIATRIC SERVICES, 2017, 68 (12) : 1217 - 1224
  • [44] Differences in Services Offered by Certified Community Behavioral Health Clinics and Community Mental Health Centers
    Wishon, Allison A.
    Brown, Jonathan D.
    [J]. PSYCHIATRIC SERVICES, 2023, 74 (04) : 411 - 414
  • [45] Relationship between patterns of cannabis use and functional and symptomatic trajectories in first-episode psychosis
    Wright, Abigail C.
    Browne, Julia
    Cather, Corinne
    Meyer-Kalos, Piper
    Mueser, Kim T.
    [J]. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2023, 273 (04) : 765 - 778